The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | JAKARTA2 update: fedratinib in MF patients previously treated with ruxolitinib
Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the efficacy and safety results of fedratinib, a selective JAK2 inhibitor, in JAKARTA2 trial (NCT01523171) patients who were resistant or intolerant to ruxolitinib. Fedratinib showed great activity, and reduced spleen volume and symptom burden in patients with myeloproliferative neoplasm-associated myelofibrosis (MF). Dr Mesa highlights how these findings help to validate the use of fedratinib in the second-line setting. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
